Canada’s Drug Agency | Drugs, Health Technologies and Systems.
Canada’s Drug Agency | Drugs, Health Technologies and Systems.

Cost-Effectiveness of Conjugate Pneumococcal Vaccines in At-Risk Adults Aged 18 to 64 Years

Details

Files
Project Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Technology Review
Project Number:
HE0054-000

What is the cost-effectiveness of the pneumococcal conjugate vaccination in adults aged 18 to 64 years who are at high risk for invasive pneumococcal disease?

Files

Cost-Effectiveness of Conjugate Pneumococcal Vaccines in At-Risk Adults Aged 18… View PDF
Last Updated : September 26, 2024